Skip to main content
. Author manuscript; available in PMC: 2016 Mar 15.
Published in final edited form as: Cancer Res. 2015 Jan 9;75(6):1046–1055. doi: 10.1158/0008-5472.CAN-14-1851

Fig. 2.

Fig. 2

ATG7 and BECN1 inhibit IRF1 and apoptosis in human ER+ breast cancer cells. A, Western blot images of IRF1, ATG5, ATG7, and BECN1 in LCC1 cells treated with vehicle, 100 nM ICI, 5 mM 3-MA, 10 μM HCQ, or transfected with ATG5, ATG7, or BECN1 siRNA for 48 hours. B-C, MCF7, LCC9, T47D, and BT-474 were transfected with Ctrl, ATG7 siRNA (B) or BECN1 siRNA (C) and the following day, treated with 100 nM ICI for 48 hours. Western blot hybridization was used to measure IRF1, ATG7, and BECN1 protein expression. D, Mitochondrial permeability assay measured by flow cytometry in LCC1 and LCC9 cells transfected with ATG7, BECN1, or control (Ctrl) siRNA. E, IRF1 expression was measured in MDA-MB-231 cells transfected with ATG7, BECN1, or Ctrl siRNA. F, LCC1 cells transfected with ATG7 cDNA or empty vector were treated with 100 nM ICI for 48 hours and expression of IRF1 and ATG7 were analyzed by Western blot. β-actin served as the loading control. n = 3 independent experiments; *P < 0.05, **P < 0.01, ***P < 0.001 versus control/vehicle experiment.